Dysmenorrhea: pathogenetic validation of pharmacotherapy
https://doi.org/10.21518/2079-701X-2018-7-23-26
Abstract
The article presents the pathogenesis aspects of dysmenorrhea based on the role of prostaglandin hyperproduction in the development of the disease. The presence of severe painful cramps in dysmenorrhea resulting in a temporary decline in labour productivity contributes to not only on a significant decrease in the patients’ quality of life, but also to economic costs. In this regard, seeking a solution to the dysmenorrhea therapy problem acquires not only medical, but also social significance. The use of nonsteroidal anti-inflammatory drugs (nimesulide) as a pathogenetically validated therapy for dysmenorrhea proves their efficiency and is a feasible option for therapy.
About the Authors
N. A. Buralkina
V.I. Kulakov National Medical Research Centre for Obstetrics, Gynaecology and Perinatology of the Ministry of Health of Russia
Russian Federation
MD
Russian Federation
MD
A. S. Katkova
V.I. Kulakov National Medical Research Centre for Obstetrics, Gynaecology and Perinatology of the Ministry of Health of Russia
Russian Federation
Russian Federation
I. A. Kiseleva
V.I. Kulakov National Medical Research Centre for Obstetrics, Gynaecology and Perinatology of the Ministry of Health of Russia
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
References
1. Prilepskaya VN. Dysmenorrhea. Ginekologiya, 2000, 2 (1): 34-39.
2. Mezhevitinova EA. Abakarova PR, Mheryan AN. Dysmenorrhea from the standpoint of evidence-based medicine. Consilium medicum, 2014, 16 (6): 83-87.
3. Mrugacz G, Grygoruk С, Sieczyński P et al. Etiopathogenesis of dysmenorrhea. Med. Wieku Rozwoj, 2013, 17(1): 85–99.
4. Jobeeva EM, Mandrykina JA. Dysmenorrhea. Etiopathogenesis, differential diagnosis and therapy in the practice of a modern obstetrician-gynecologist. Akusherstvo i Ginekologiya, 2012, 4 (1).
5. Serov VN, Uvarova EA, Gainova IG. Modern possibilities for the use of nonsteroidal anti-inflammatory drugs for elimination and prevention of dysmenorrhea. Farmateka, 2004, 15 (92): 18-24.
6. Harada T. Dysmenorrhea and endometriosis in young women. Yonago Acta Med, 2013, 56(4): 81–84.
7. Markov KhM. Prostaglandins. Uspekhi Fiziologicheskikh Nauk, 1970, I (14): 98-125.
8. Yui K, Imataka G, Nakamura H, Ohara N, Naito Y. Eicosanoids Derived From Arachidonic Acid and Their Family Prostaglandins and Cyclooxygenase in Psychiatric Disorders. Curr Neuropharmacol, 2015, Nov 1.
9. Xu K, Chen L, Fu L, Xu S, Fan H, Gao Q, Xu Y, Wang W. Stressful Parental-Bonding Exaggerates the Functional and Emotional Disturbances of Primary Dysmenorrhea. Int J Behav Med, 2016 Aug, 23(4): 458-463.
10. Onaka Y, Shintani N, Nakazawa T, Haba R, Ago Y, Wang H et al. CRTH2, a prostaglandin D2 receptor, mediates depression-related behavior in mice. Brain Res, 2015, May 1, 284: 131-137.
11. Moldavan M, Cravetchi O, Williams M, Irwin RP, Aicher SA, Allen CN. Localization and expression of GABA transporters in the suprachiasmatic nucleus. Eur J Neurosci, 2015, Sep 22.
12. Kulakov VI, Uvarova EV. Standard principles of examination and treatment of children and adolescents with gynaecological diseases and disorders of sexual development. M: Triada-X, 2004.
13. Marjoribanks J, Proctor ML, Farquhar C, Derks RS. Nonsteroidal anti-inflammatory drugs for dysmenorrhea. Cochrane Database Syst Rev, 2010, 20(1).
14. Uvarova EV. Abnormal uterine bleeding in puberty period. Reprodukt. Zdorovye Detey i Podrostkov, 2018, 1: 64-91.
Review
For citations:
Buralkina NA, Katkova AS, Kiseleva IA. Dysmenorrhea: pathogenetic validation of pharmacotherapy. Meditsinskiy sovet = Medical Council. 2018;(7):23-26. (In Russ.) https://doi.org/10.21518/2079-701X-2018-7-23-26
Views:
734
Email this article 